The results suggested that MPO levels were significantly lowered in the h‐mIL‐6R mAb‐ and Tocilizumab‐treated SIRS mice (Figure 3D), suggesting that inflammation in lung tissue was lessened by the IL‐6R mAbs. Here, IL6R is linked to systemic inflammatory response syndrome.